DCLK1 and neoplasm: Then, the GEO dataset (GSE103668) including 21 TNBC patients treated with cisplatin & bevacizumab before surgery were analyzed and results revealed that patients with no significant reduction in tumor size, also ranked as Miller-Payne (MP) grade 1 according to Miller-Payne response score tended to express higher DCLK1 levels than patients with tumor reduction of more than 90%, also known as MP grade 4 (Fig. 2d).